Abstract
Spondyloartrhitis (SpA) are a group of diseases characterized by inflammation at articular and entheseal sites. Moreover, patients with SpA suffer from impaired articular function and reduced quality of life. Beyond the articular involvement, SpA and in particular psoriatic arthritis (PsA) are associated with extra-articular manifestations and comorbidities that might increase the burden of the disease. The aim of this article was to review the available evidences on the presence of comorbidities in SpA, including PsA, focusing the attention on the cardiovascular, metabolic aspects, as well as other comorbidities, and their possible management in an integrated manner. Comorbidities in SpA should be carefully evaluated because of their important impact.
Similar content being viewed by others
References
Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127–2137
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J et al (2009) The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31
Lubrano E, De Socio A, Perrotta FM (2017) Unmet needs in axial spondyloarthritis. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-017-8637-0
De Socio A, Perrotta FM, Grasso GM, Lubrano E (2018) Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of Central Italy: results of the CAMPO-RHE study. Postgrad Med 130:137–141
Lubrano E, Perrotta FM (2017) The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 13:815–821
Lubrano E, Perrotta FM (2016) Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag 12:1587–1592
Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A (2017) A national survey on the management of psoriatic arthritis using the Delphi method. Clin Exp Rheumatol 35:214–220
Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D’Angelo S, Mathieu A et al (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35:991–1010
Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43:350–355
Lubrano E, Perrotta FM, Marchesoni A, D’Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 42:258–263
Papagoras C, Voulgari PV, Drosos AA (2013) Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 31:612–620
Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44:1298–1301
Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70:1921–1925
Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima- media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47:1203–1207
Perrotta FM, Scarno A, Carboni A, Bernardo V, Montepaone M, Lubrano E, Spadaro A (2013) Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices. Reumatismo 65:105–112
Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69:1165–1168
Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL (2016) Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 35:3069–3073
Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH (2014) Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of develo** type 2 diabetes in an Asian population. Rheumatol Int 34:265–270
Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:557–563
Ingegnoli F, Gualtierotti R, Artusi C, Lubrano E (2014) Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. Expert Rev Clin Immunol 10:307–315
van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE (2012) High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 31:1529–1535
van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, Dijkmans BA, Heymans MW, Lems WF (2012) High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 23:1683–1690
Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S, Carmona L (2017) Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48:44–52. https://doi.org/10.1016/j.semarthrit.2017.12.001
Pray C, Feroz NI, Haroon N (2017) Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int 101:182–192
Mease PJ (2017) Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol 29:304–310
Moltó A, Etcheto A, Gossec L, Boudersa N, Claudepierre P, Roux N, Lemeunier L, Martin A, Sparsa L, Coquerelle P, Soubrier M, Perrot S, Dougados M (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77:533–540
Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132
Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbasi-Zender E, Schmitz-Bortz E, Braun J (2017) Patients with fibromyalgia rarely fulfill classification criteria for axial spondyloarthritis. Rheumatology (Oxford) 57(2017):1541–1547. https://doi.org/10.1093/rheumatology/kex318
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24–31
Chan CYY, Tsang HHL, Lau CS, Chung HY (2017) Prevalence of depressive and anxiety disorders and validation of the hospital anxiety and depression scale as a screening tool in axial spondyloarthritis patients. Int J Rheum Dis 20:317–325
Meesters JJ, Bremander A, Bergman S, Petersson IF, Turkiewicz A, Englund M (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16:418
Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U (2012) Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 32:323–330
Cutolo M, Paolino S, Pizzorni C (2014) Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol 32:839–847
Chang CC, Chang CW, Nguyen PA, Chang TH, Shih YL, Chang WY et al (2017) Ankylosing spondylitis and the risk of cancer. Oncol Lett 14:1315–1322
Deng C, Li W, Fei Y, Li Y, Zhang F (2016) Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep 6. https://doi.org/10.1038/srep32063
Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F (2016) Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15:35–54
van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF et al (2016) Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75:83–98
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110
Radner H, Lesperance T, Accortt NA, Solomon DH (2017) Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken) 69:1510–1518
Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature. https://doi.org/10.1038/nature05485
Hutcheson J (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:272–279. https://doi.org/10.1016/j.cyto.2015.04.004
Chehimi M, Vidal H, Eljaafari A (2017) Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 6:68
Fassio A, Gatti D, Gisondi P, Girolomoni G, Viapiana O, Giollo A (2017) Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo 69:105–110. https://doi.org/10.4081/reumatismo.2017.953
Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202
Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their cor- relation with disease activity. Ann Rheum Dis 72:1956–1961
Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43:463–464
Eder L, Chandran V, Cook R, Gladman DD (2017) The risk of develo** diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol 44:286–291
Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:500–512
Busquets N, Vaquero CG, Moreno JR, Vilaseca DR, Narváez J, Carmona L, Nolla JM (2014) Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Reumatol Clin 10:89–93
Gulati AM, Hoff M, Salvesen Ø, Dhainaut A, Semb AG, Kavanaugh A, Haugeberg G (2017) Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag health study 3. RMD Open 3:e000413
Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A et al (2012) Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 39:849–855
Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Mathieu S, Couderc M, Soubrier M, Dubost JJ (2017) Frequency of concomitant fibromyalgia in rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 47:129–132
Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H et al (2018) The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford) 57:32–40
Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749–1754
McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887–896
Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351–360
Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ (2017) Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol 31:1999–2009
Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126:2194–2201
Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140:237–242
Wilton KM, Crowson CS, Matteson EL (2016) Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clin Rheumatol 35:2603–2607
Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G (2015) Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14:706–714
Lubrano E, Perrotta FM (2017) Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 36:2633–2635
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Scriffignano, S., Perrotta, F.M., De Socio, A. et al. Role of comorbidities in spondyloarthritis including psoriatic arthritis. Clin Rheumatol 38, 3–10 (2019). https://doi.org/10.1007/s10067-018-4332-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4332-7